May 3, 2007Open Access

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Key Points

Key points are not available for this paper at this time.

Abstract

A once-yearly infusion of zoledronic acid during a 3-year period significantly reduced the risk of vertebral, hip, and other fractures. (ClinicalTrials.gov number, NCT00049829.)

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Discussion

Authors

Dennis M. Black

Pierre D. Delmas

Richard Eastell

Journals

New England Journal of Medicine

Actions

Institutions

University of California, San Francisco

Inserm

University of Pittsburgh

References and Citations

Connected Papers

Building similarity graph...

Analyzing shared references across papers

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis

Key Points

Abstract

Citation Network

Connected Papers

Discussion

Authors

Journals

Actions

Institutions

References and Citations

Citation Network

Connected Papers

Discussion

Cite this study